The Cancer Moonshot Immuno-Oncology Translational Network at 5: accelerating cancer immunotherapies
Year: 2023
Type: article
Abstract: The Immuno-Oncology Translational Network (IOTN) was established in 2018 as part of the Cancer Moonshot. In 2022, President Joe Biden set new goals to reduce the cancer death rate by half within 25 years and improve the lives of people with cancer and cancer survivors. The IOTN is focused on accelerating translation of cancer immunology research, from bench to bedside, and improving immunotherapy outcomes across a wide array of cancers in the adult population. The unique structure and team science approach of the IOTN is designed to accelerate discovery and evaluation of novel immune-based therapeutic and prevention strategies. In this article, we describe IOTN progress to date, including new initiatives and the development of a robust set of resources to advance cancer immunology research. We summarize new insights by IOTN researchers, some of which are ripe for translation for several types of cancers. Looking to the future, we identify barriers to the translation of immuno-oncology concepts into clinical trials and key areas for action and improvements that are suitable for high-yield investments. Based on these experiences, we recommend novel National Institutes of Health funding mechanisms and development of new resources to address these barriers.
DOI: 10.1093/jnci/djad151
Institutions: Baylor College of Medicine, Texas Children's Hospital, The University of Texas MD Anderson Cancer Center, Roswell Park Comprehensive Cancer Center, University of California, Irvine, University of California, San Francisco, Parker Institute for Cancer Immunotherapy, Harold C. Simmons Comprehensive Cancer Center, The University of Texas Southwestern Medical Center, Harvard University, Dana-Farber Cancer Institute, University of Wisconsin–Madison, University of Chicago, University of Chicago Medicine Comprehensive Cancer Center
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,978
Awards: G1129313267, Nano-Immuno-Oncology Approaches to Overcome Tumor Immune Evasion, G1308892644, MUC1-C is a Target for Reversing Immune Evasion and Resistance to Immunotherapies, G3742884323, G3826224914, G4150478258, G4700107717, Immunomodulation of the Tumor Microenvironment with Molecular Targeted Radiotherapy to Facilitate an Adaptive Anti-Tumor Immune Response to Combined Modality Immunotherapies, G6521172848, U01 Proposal Transfer - 2021, G7340370193, G8430319597, G9000007066, G9000024339, G9000031074, G9000071351, G9000107059, G9000232656
OpenAlex ID: W4385784118